• Search
  • Advanced Search
Clin Mol Hepatol > Accepted Articles
Editorial
TM4SF1 - A new immune target for treatment of hepatocellular carcinoma
Chen Rui YUAN1, Terence Kin Wah LEE1,2
1Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University
2State Key Laboratory of Chemical Biology and Drug Discovery, The Hong Kong Polytechnic University
Correspondence :  Terence Kin Wah LEE ,
Tel: (852) 3400-8799, Fax: (852) 2364-9932, Email: terence.kw.lee@polyu.edu.hk
Received: January 29, 2025   Accepted: February 6, 2025
TOOLS
METRICS Graph View
  • 0 Crossref
  •  0 Scopus
  • 259 View
  • 23 Download
Related articles

Tetraspan(in)-mediated immune regulation in hepatocellular carcinoma

Targeting TM4SF1 to overcome immunotherapy resistance in hepatocellular carcinoma

Conventional and machine learning-based risk scores for patients with early-stage hepatocellular carcinoma2024 July;30(3)

Novel paradigm in the treatment of hepatocellular carcinoma: Anticipating breakthroughs with particle therapy2023 October;29(4)

Chemoembolization combined with radiofrequency ablation is the best option for the local treatment of early hepatocellular carcinoma?2023 October;29(4)

Editorial Office
The Korean Association for the Study of the Liver
Room A1210, 53 Mapo-daero(MapoTrapalace, Dowha-dong), Mapo-gu, Seoul, 04158, Korea
TEL: +82-2-703-0051   FAX: +82-2-703-0071    E-mail: cmh_journal@ijpnc.com
Copyright © The Korean Association for the Study of the Liver.         
COUNTER
TODAY : 1598
TOTAL : 2562630
Close layer